Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
WHO compiles a list of antibacterials in clinical development on a regular basis, the last in mid-2024 [1]. The information is up-to-date and detailed: it provides MoA and antibacterial spectrum, coverage of problem pathogens, the development phase, and whether it Continue reading A Critical Review of WHO’s List of Antibacterials in Clinical Development
Since the beginning of this millennium we have seen antibiotic R&D dwindle year after year. There are many reasons for this; while economics are often cited for this decline, the FDA and the ‘Guideline Wars’, i.e., those never ending discussions Continue reading Progress Report: New Antibacterials In the Fight against MDR Bacteria
A recent letter to the Editor by Simkins et al. is worth reviewing [1]. The authors describe the complicated course of a patient who suffered graft rejection after liver transplantation, received broad-spectrum antibiotics during prolonged hospitalization and eventually had a Continue reading IV Fosfomycin To The Rescue – And To a Place Near You
80% of antibiotics worldwide are used in veterinary medicine. With only a minor fraction metabolized to inactive compounds, there are plenty of antibiotics excreted by farm animals in unchanged active form. These antibiotic residues are found in manure, in the Continue reading Food for Thought, Sprinkled With Small Amounts of Antibiotic Residues
When older drugs get reintroduced into clinical practice because pathogens have developed resistance to newer agents, it comes at the price of uncertainty. Often, older drugs were approved based on rather limited data, often considered incomplete by today’s standards. Take colistin Continue reading Nitrofurantoin – An Old Drug Resurrected Needs Prospective Scrutiny